Sponsorship from organisations across the health and social care sector ensures Health and Care Innovation Expo is a high-quality event, with free-of-charge tickets available to public sector colleagues, while remaining cost-neutral to the NHS.
At Expo 2016, sponsorship of our feature zones helped these areas become even more interactive and engaging. The Personalised Medicine Zone was sponsored by Merck Serono; the NHS RightCare Zone was sponsored by Roche; the New Care Models Zone was sponsored by MSD, and the Digital Health Zone was sponsored by Teva.
To discuss opportunities and have a chat about your needs for Expo 2017, on 11 and 12 September 2017, please call 0207 593 5500 or email firstname.lastname@example.org
Merck discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. Merck has an enduring commitment to deliver novel therapies in its core focus areas of neurology, oncology, immuno-oncology and immunology, supporting patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. Merck has a robust pipeline of potential therapies in oncology, immuno-oncology and immunology.
Personalised Medicine Zone
MSD is a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, NJ and USA. Through its prescription medicines, biologic therapies and animal health products, the organisation works with customers and operates in more than 140 countries to deliver innovative health solutions. MSD also demonstrates its commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships.
Website: www.msd-uk.com New Care Models Zone
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases and neuroscience. Roche is also the world leader in vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management. Roche’s personalised healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in health, quality of life, safety and survival of patients. Twenty-eight medicines developed by Roche are included in the WHO Model Lists of Essential Medicines; among them life-saving antibiotics, antimalarials and chemotherapy. Roche in the UK employs over 2,000 people in pharmaceuticals and diagnostics.
Teva is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients around the world. Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In the UK, we supply more packs of medicine to the NHS than anyone else, and in specialty medicines, we have a world-leading position in innovative treatments for disorders of the central nervous system, including multiple sclerosis and pain, as well as a strong portfolio of respiratory medicines. We integrate our generics and specialty capabilities in our global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. From the traditional digital app to cutting-edge microchip technology, our digital health solutions run across generics and specialty medicines. Our solutions start with The Triple Aim: To improve healthcare; enhance the patient/care provider experience; and reduce cost or time.